The effect of posterior subtenon methylprednisolone acetate in the refractory diabetic macular edema: a prospective nonrandomized interventional case series.
BACKGROUND
To investigate the efficacy of posterior subtenon methylprednisolone acetate injection in treatment of refractory diffuse clinically significant diabetic macular edema (CSME).


METHODS
In a prospective, nonrandomized, interventional case series, 52 eyes were diagnosed with CSME and treated with at least two sessions of laser photocoagulation according to Early Treatment Diabetic Retinopathy Study guidelines. At least 3 months after laser therapy, eyes with a residual central macular thickness were offered posterior subtenon injection of 40 mg methylprednisolone acetate. Main outcome measures were visual acuity, macular thickness and intraocular pressure. Potential complications were monitored, including intraocular pressure response, cataract progression and scleral perforation.


RESULTS
Mean baseline visual acuity (in logMAR) improved significantly (p = 0.003) from 0.8 +/- 0.36 to 0.6 +/- 0.41 at 3 months. Mean foveal thickness decreased from 388 +/- 78 mum at baseline to 231 +/- 40 mum after 3 months (p < 0.0001). Visual acuity improvement in eyes with CSME with extrafoveal hard exudates was significant (p = 0.0001), but not significant in eyes with CSME with subfoveal hard exudates (p = 0.32). Intraocular pressure increased from 14.7 +/- 2.0 mmHg (range, 12-18 mmHg) to a maximum value of 15.9 +/- 2.1 mmHg (range, 12-20 mmHg) during the follow-up period. Complications in two eyes developed focal conjunctival necrosis at the site of injection.


CONCLUSIONS
Posterior subtenon methylprednisolone acetate may improve early visual outcome in diffuse diabetic macular edema that fails to respond to conventional laser photocoagulation. Visual acuity improvement in eyes with CSME with extrafoveal hard exudates was significant; and this improvement is depends on location of hard exudates. Further study is needed to assess the long-term efficacy, safety, and retreatment.
Javadzadeh
Alireza
A
Retina service, Department of Ophthalmology, Nikookari Hospital--Drug of applied research center, Tabriz University of Medical Sciences, Tabriz, Iran. javadzadehalireza@yahoo.com
D000328:Adult; D000368:Aged; D003238:Connective Tissue; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D005123:Eye; D005260:Female; D006801:Humans; D007267:Injections; D017075:Laser Coagulation; D008269:Macular Edema / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077555:Methylprednisolone Acetate; D008875:Middle Aged; D011446:Prospective Studies; D019233:Retreatment; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity
D000077555:Methylprednisolone Acetate; D008775:Methylprednisolone